Celldex Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celldex Therapeutics, Inc.
While Amicus will transfer the gene therapy portfolio’s R&D risk to Caritas, it retains a financial interest in many of the spinout’s programs. Pompe candidate AT-GAA accepted for FDA review.
The market for surgical heart valve replacement devices is projected to steadily decline, as newer, more innovative transcatheter techniques poach customers, according to a new report from Informa’s Meddevicetracker.
After three failures in quick succession, Merck needs to see a win in one of its many remaining Phase II trials.
Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.
- Other Names / Subsidiaries
- Avant Immunotherapeutics, Inc.
- CuraGen Corporation
- Kolltan Pharmaceuticals, Inc.
- Xetrios Therapeutics Inc.